Fig. 3

A Schematic representation of the CSMs safety. Blood samples and MRI were analyzed before and 24 h, 3 days and 7 days after the CSM@rtPA administration. B T2 and T2*-weighted images MRI showed that hemorrhages or ischemic damages were not found. Furthermore, the analysis of C GOT and D GPT as hepatic markers demonstrated that CSM@rtPA did not provoke toxicity in the liver and kidneys. These data are represented as mean ± SEM (n = 3 per group of treatment). Statistical analysis was assessed by Kruskal–Wallis test followed by Dunn’s test compared with the basal. E To study the inflammatory response alteration blood samples were extracted before and 6 h, 24 h, 3 days, and 7 days after the CSM@rtPA administration. Levels of IL-6 (F) did not change over the days. The dotted lines represented the detection range of the ELISA kit. These data are represented as mean ± SEM (n = 5 per group of treatment). Statistical analysis was assessed by Kruskal–Wallis test followed by Dunn’s multiple test compared with the corresponding basal timepoint